Strong sales growth and higher margins boosted third-quarter post-tax profits at Elan by 37 per cent, to $183.5 million (€205 million). The pharmaceutical group reported earnings per share ahead of ...
A safety evaluation of Elan's controversial drug Tysabri has found no new confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis, the company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback